

Jean-Philippe Guilloux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7651496/publications.pdf>

Version: 2024-02-01

44
papers

4,239
citations

147726

31
h-index

214721

47
g-index

47
all docs

47
docs citations

47
times ranked

5667
citing authors

#	ARTICLE	IF	CITATIONS
1	Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens. <i>Neuroscience Research</i> , 2018, 134, 56-60.	1.0	11
2	Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. <i>Frontiers in Pharmacology</i> , 2018, 9, 204.	1.6	8
3	S 38093, a histamine H3 antagonist/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice. <i>Scientific Reports</i> , 2017, 7, 42946.	1.6	29
4	Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice.. <i>Experimental and Clinical Psychopharmacology</i> , 2017, 25, 94-104.	1.3	45
5	S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms. <i>Frontiers in Pharmacology</i> , 2017, 8, 462.	1.6	47
6	Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 237.	1.8	29
7	Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. <i>Pharmaceuticals</i> , 2016, 9, 9.	1.7	71
8	Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments. <i>Psychopharmacology</i> , 2016, 233, 3297-3314.	1.5	18
9	Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. <i>Journal of Neuroscience</i> , 2016, 36, 518-531.	1.7	94
10	The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. <i>L'Encephale</i> , 2016, 42, 156-164.	0.3	44
11	Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. <i>Neuropharmacology</i> , 2016, 105, 142-153.	2.0	32
12	Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression. <i>Neuroscience Letters</i> , 2016, 616, 197-203.	1.0	23
13	Molecular and Genetic Characterization of Depression: Overlap with Other Psychiatric Disorders and Aging. <i>Molecular Neuropsychiatry</i> , 2015, 1, 1-12.	3.0	56
14	Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression. <i>Neuropsychopharmacology</i> , 2015, 40, 701-710.	2.8	58
15	Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. <i>Journal of Affective Disorders</i> , 2015, 175, 233-240.	2.0	44
16	Vortioxetine for the treatment of major depressive disorder. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 731-745.	1.3	22
17	Learning and memory impairments in a neuroendocrine mouse model of anxiety/depression. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 136.	1.0	96
18	NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration. <i>Neuroscience</i> , 2014, 274, 357-368.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. <i>Neuropharmacology</i> , 2013, 73, 147-159.	2.0	108
20	Anticipated Brain Molecular Aging in Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 450-460.	0.6	53
21	Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 321-335.	1.0	91
22	Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. <i>Molecular Psychiatry</i> , 2012, 17, 1130-1142.	4.1	311
23	Brain-Derived Neurotrophic Factor Signaling and Subgenual Anterior Cingulate Cortex Dysfunction in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2012, 169, 1194-1202.	4.0	221
24	Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT1A and 5-HT1B receptors disruption in mice. <i>Neuroscience Letters</i> , 2012, 521, 20-25.	1.0	34
25	Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. <i>Psychopharmacology</i> , 2012, 220, 1-14.	1.5	49
26	Anticipated Brain Molecular Aging in Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	0.6	2
27	Characterization of 5-HT1A/1B ^Δ /Δ ⁺ mice: An animal model sensitive to anxiolytic treatments. <i>Neuropharmacology</i> , 2011, 61, 478-488.	2.0	38
28	Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: Relevance to emotionality and sex. <i>Journal of Neuroscience Methods</i> , 2011, 197, 21-31.	1.3	242
29	A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. <i>European Journal of Pharmacology</i> , 2010, 628, 83-90.	1.7	55
30	Network analysis of positional candidate genes of schizophrenia highlights more than myelin-related pathways. <i>Molecular Psychiatry</i> , 2010, 15, 786-788.	4.1	7
31	Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice. <i>PLoS ONE</i> , 2010, 5, e9777.	1.1	78
32	Altered Gene Synchrony Suggests a Combined Hormone-Mediated Dysregulated State in Major Depression. <i>PLoS ONE</i> , 2010, 5, e9970.	1.1	38
33	Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. <i>European Journal of Neuroscience</i> , 2009, 30, 397-414.	1.2	78
34	Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 23-42.	1.0	36
35	Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/Depression. <i>Neuron</i> , 2009, 62, 479-493.	3.8	1,080
36	Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: Studies in adult mice hippocampus. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 174-183.	1.3	50

#	ARTICLE	IF	CITATIONS
37	A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Archives of Cardiovascular Diseases, 2008, 101, 723-735.	0.7	6
38	Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology, 2008, 55, 1006-1014.	2.0	136
39	Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex. Molecular Pharmacology, 2007, 72, 1411-1418.	1.0	36
40	Targeted In Vivo Expression of Nicotinic Acetylcholine Receptors in Mouse Brain Using Lentiviral Expression Vectors. Journal of Molecular Neuroscience, 2006, 30, 105-106.	1.1	10
41	Blockade of 5-HT _{1A} Receptors by (±)-Pindolol Potentiates Cortical 5-HT Outflow, but not Antidepressant-Like Activity of Paroxetine: Microdialysis and Behavioral Approaches in 5-HT _{1A} Receptor Knockout Mice. Neuropsychopharmacology, 2006, 31, 2162-2172.	2.8	63
42	Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature, 2005, 436, 103-107.	13.7	548
43	Rapid and precise method to locate microdialysis probe implantation in the rodent brain. Journal of Neuroscience Methods, 2004, 140, 53-57.	1.3	49
44	Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. Journal of Neurochemistry, 2004, 89, 54-63.	2.1	60